Holdings
Atle Fund Management AB
As of Sep 30, 2026, Atle Fund Management AB reported 37 positions worth US$360M. Largest: Eli Lilly and Company, Merck & Company, Inc. and Johnson & Johnson. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly and Company | 31,202 | US$36.1M | +1,381 | Sep 30, 2026 |
| Merck & Company, Inc. | 169K | US$24.6M | −20,370 | Sep 30, 2026 |
| Johnson & Johnson | 91,387 | US$24.2M | +5,962 | Sep 30, 2026 |
| AbbVie Inc. | 91,294 | US$23.9M | +26,969 | Sep 30, 2026 |
| Thermo Fisher Scientific Inc | 34,410 | US$23.2M | +6,551 | Sep 30, 2026 |
| Biogen Inc. | 70,955 | US$16M | +8,174 | Sep 30, 2026 |
| Vertex Pharmaceuticals Incorporated | 28,157 | US$14.7M | +9,026 | Sep 30, 2026 |
| Revolution Medicines, Inc. | 66,113 | US$13.6M | −6,964 | Sep 30, 2026 |
| BeOne Medicines Ltd. Class A | 35,679 | US$13.1M | +499 | Sep 30, 2026 |
| CVS Health Corporation | 139K | US$11.9M | −6,791 | Sep 30, 2026 |